Chongqing Zhifei Biological Products Co., Ltd. Class A

Chongqing Zhifei Biological Products Co., Ltd. Class A

SSZSE:300122
13.54
CNY
-0.07
(-0.51%)
-5.89EPS
33.47BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.33
0.28
0.18
0.54
2.12
4.3
6.16
12.44
15.94
22.07
10.88
3.74
3.28
Basic EPS, GAAP
0.05
0.06
0.08
0.01
0.18
0.59
0.96
1.34
4.14
3.14
3.38
0.82
-6.15
-5.88
Free Cash Flow per Basic Share
0.01
-0.05
- -
-0.09
-0.01
0.04
0.32
1.08
2.67
0.22
3.28
-2.26
1.9
- -
Dividend per Share
0.05
0.03
0.03
0.03
0.01
0.1
0.35
0.38
0.35
0.42
0.37
1.07
0.14
0.15
Book Value per Share
0.97
1
1
1.02
1.19
1.7
2.33
3.35
7.17
9.84
13.14
12.89
6.62
6.33
Tangible Book Value per Share
0.85
0.88
0.88
0.89
1.06
1.54
2.14
3.08
6.84
9.4
12.58
12
5.53
5.19
Basic Weighted Avg Shares
2,509
2,399
2,533
2,504
2,464
2,464
2,464
2,464
2,464
2,400
2,400
2,395
2,394
2,394
Sales/Revenue/Turnover
780
801
713
446
1,343
5,228
10,587
15,190
30,652
38,264
52,963
26,049
8,958
7,853
Operating Margin (%)
20.83
20.08
28.24
11.04
40.78
34.52
28.11
27.45
40.16
24.31
19.05
11.34
-33.73
-33.68
Depreciation Expense
25
32
41
54
61
85
89
121
376
315
324
395
515
- -
Net Income, GAAP
130
148
197
33
432
1,451
2,366
3,301
10,209
7,539
8,108
1,972
-14,723
-14,079
Effective Tax Rate (%)
14.66
15.55
14.43
9
14.35
14.23
14.43
14.34
14.44
13.52
13.63
10.27
- -
- -
Profit Margin (%)
16.71
18.48
27.7
7.29
32.2
27.76
22.35
21.73
33.3
19.7
15.31
7.57
-164.35
-179.28
Working Capital
1,614
1,489
1,234
1,038
1,216
2,081
3,095
4,720
12,883
18,183
24,465
22,542
6,615
9,529
LT Debt
- -
54
- -
- -
- -
- -
- -
5
249
238
353
1,259
2,918
6,495
Total Equity
2,389
2,458
2,469
2,521
2,938
4,181
5,747
8,249
17,657
24,236
31,544
30,851
16,106
15,401
Return on Invested Capital (%)
5.37
5.96
7.62
1.06
15.44
36.52
36.76
33.83
65.81
32.72
26.99
5.23
- -
- -
Return on Capital (%)
4.58
6.04
7.93
1.3
15.35
36.87
37.6
35.42
69.3
33.9
26.88
5.43
- -
- -
Return on Common Equity (%)
5.47
6.11
8.01
1.3
15.84
40.78
47.67
47.18
78.81
35.99
29.07
6.32
-63.06
-63.04

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3,438
2,994
2,151
LT Borrowings
7,858
7,188
6,481
LT Finance Leases
8
6
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,394
2,394
2,394
Market Capitalization
35,811
27,983
33,465

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
16,418
15,071
14,491
Cash, Cash Equivalents & STI
1,709
2,105
2,319
Accounts Receivable, Net
10,925
10,377
9,954
Inventories
3,573
2,403
2,003
Total Current Liabilities
5,228
5,064
4,962
Payables & Accruals
- -
- -
- -
ST Debt
3,438
2,994
2,151
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.34%
26.3%
-47.79%
Free Cash Flow
1,090.1%
213.73%
-183.83%
Net Income, GAAP
75.26%
-146.29%
-846.42%
Sales/Revenue/Turnover
64.76%
9.72%
-65.61%
Total Cash Common Dividend
120.3%
20%
-86.55%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,416
6,857
4,514
3,262
26,049
2025
2,354
2,572
2,719
1,314
8,958
2026
2,150
1,874
2,515
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.61
0.32
-0.04
-0.06
0.82
2025
-0.14
-0.11
-0.3
-5.6
-6.15
2026
-0.16
-0.18
0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.81
0.22
1.07
2025
0.03
0.03
- -
0.03
0.14
2026
0.05
0.04
0.04
- -
- -

Company Description

CEO
Ling Feng Jiang
Full Time Employees
6,292
Sector
Health technology
Industry
Biotechnology
Address
Building T1, IFS Chongqing CH China 400020
IPO Date
Sep 10, 2010
Business
Chongqing Zhifei Biological Products Co., Ltd. Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) engages in the research, development, production, marketing, distribution, import, and export of vaccines and biological products primarily in China. Founded in 2002 and headquartered in Chongqing, the company operates through subsidiaries including Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., serving infants, adolescents, and adults with a focus on preventing infectious diseases such as meningitis, pneumonia, tuberculosis, influenza, rotavirus gastroenteritis, cervical cancer, and herpes zoster. Its core proprietary products encompass Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc), Meningococcal Group A and C Conjugate Vaccine (Mening A Con), Haemophilus Influenzae Type b Conjugate Vaccine (XiFeiBei), AC Meningococcal Polysaccharide Vaccine (Mengnake), Recombinant Novel Coronavirus Vaccine (CHO Cell; Zifivax), Recombinant Mycobacterium Tuberculosis Fusion Protein (EC; Ekear), Mycobacterium Vaccae for Injection (Vaccae), and 23-valent Pneumococcal Polysaccharide Vaccine; as the exclusive distributor for imported vaccines, it offers Merck Sharp & Dohme products including four-valent and nine-valent Human Papillomavirus Vaccines (Gardasil and Gardasil 9), five-valent Rotavirus Vaccine (Rotateq), 23-valent Pneumococcal Vaccine (Pneumovax 23), and Hepatitis A Vaccine (Vaqta), alongside GlaxoSmithKline's Recombinant Zoster Vaccine (Shingrix). In December 2024, the company signed a supplementary agreement with GlaxoSmithKline to extend exclusive importation, distribution, and joint promotion rights for Shingrix in mainland China through 2034, with potential volumes valued at £2.3 billion to GlaxoSmithKline over 2024-2029 and exploration of collaboration on an RSV vaccine; earlier in 2024, MSD's HPV vaccines gained approval for male indications in China, enhancing herd immunity efforts, while proprietary products like the TB diagnostic Ekear joined the National Reimbursement Drug List and AC polysaccharide vaccine secured national procurement bids. The company maintains a "production determined by sales" model with nationwide direct sales via over 30,000 vaccination points, invests heavily in R&D (RMB 1.39 billion in 2024 across influenza, pneumococcal, meningococcal, and multivalent vaccines), and pursues international expansion including approvals in Indonesia and ongoing registrations in high-TB-burden countries.